PDE4B and idiopathic pulmonary fibrosis: BI 1015550, a phosphodiesterase 4B (PDE4B) inhibitor developed by Boehringer Ingelheim, is currently undergoing clinical trials for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) [26].